Search Result

Results for "

left ventricular

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (2) Biochemical Assay Reagents (1) Endogenous Metabolite (2) Isotope-Labeled Compounds (2) MMP (1) Myosin (1) Neprilysin (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (7) Sodium Channel (1)
By Research Areas:	Cardiovascular Disease (21) Inflammation/Immunology (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0259

Indapamide	Potassium Channel	Cardiovascular Disease
Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-101415

Coenzyme Q9 Ubiquinone Q9; CoQ9; Ubiquinone 9	Apoptosis Endogenous Metabolite	Cardiovascular Disease
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

HY-107428

PD-166793	MMP	Cardiovascular Disease
PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC₅₀=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC₅₀=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .

HY-106369

HMR 1556 1 Publications Verification	Potassium Channel	Cardiovascular Disease
HMR 1556, a chromanol derivative, is a potent I_Ks blocker with IC₅₀s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively .

HY-B0259A

Indapamide hemihydrate	Potassium Channel	Cardiovascular Disease
Indapamide hemihydrate is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide hemihydrate is also can reduce left ventricular hypertrophy .

HY-120355

AP14145	Potassium Channel	Cardiovascular Disease
AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits K_Ca2.2 channel and K_Ca channel with IC₅₀ of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .

HY-101415R

Coenzyme Q9 (Standard)	Apoptosis Endogenous Metabolite	Cardiovascular Disease
Coenzyme Q9 (Standard) is the analytical standard of Coenzyme Q9. This product is intended for research and analytical applications. Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

HY-121460

Spiraprilat	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF) .

HY-116478

L-3373	Others	Others
L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.

HY-106024A

Alagebrium bromide ALT711 bromide		Cardiovascular Disease
Alagebrium bromide is an analog of Alagebrium Chloride (HY-106024B), a glucose cross-link blocker. Alagebrium Chloride disrupts glucose cross-links and may improve ventricular and arterial compliance. Alagebrium Chloride improves left ventricular diastolic filling and has the potential to inhibit diastolic heart failure (DHF) .

HY-19121

TCV-309	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function .

HY-116119

BDF 9148	Sodium Channel	Cardiovascular Disease
BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .

HY-120298

LY-510929	Others	Others
LY-510929 is a compound that induces left ventricular hypertrophy (LVH). Related studies have identified the relevant conditions in which LY-510929 may induce LVH by measuring multiple markers and using multiple techniques.

HY-114683

KS370G	Others	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .

HY-119817

Flosequinan BTS 49465; Flosequinon	Others	Cardiovascular Disease
Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure .

HY-B0259S3

Indapamide-d6	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
Indapamide-d6 is a deuterated labeled Indapamide . Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-B0259S

(rac)-Indapamide-d3	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
(rac)-Indapamide-d₃ is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy[1][4].

HY-B0259R

Indapamide (Standard)	Potassium Channel	Cardiovascular Disease
Indapamide (Standard) is the analytical standard of Indapamide. This product is intended for research and analytical applications. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-W722221

Colterol acetate	Adrenergic Receptor	Cardiovascular Disease
Colterol acetate is a selective inhibitor of β-adrenergic receptors. Colterol acetate can relax tracheal smooth muscle (primarily acting on β2 receptors), reduce subspastic contractions of tricholoma (acting on β2), and increase contractility of left ventricular papillary muscles (acting on β1) .

HY-129706

LY127210 free base	Others	Cardiovascular Disease
LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .

HY-W145695

Chitoheptaose	Biochemical Assay Reagents	Inflammation/Immunology
Chitoheptaose is a chitosan oligosaccharide. Chitoheptaose is capable of extracting exoskeletons from crustaceans, such as the shells of crabs, shrimp and lobsters. Chitoheptaose has antioxidant, anti-inflammatory and anti-apoptotic activities and can be used in the study of myocarditis. Chitoheptaose has cardioprotective effects and improves cardiac parameters (left ventricular internal size, end-systolic and end-diastolic, ejection fraction and shortening fraction), inflammatory cytokines (IL-1β) in vanishing models .

HY-163120

Myosin-IN-1	Myosin	Cardiovascular Disease
Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .

HY-118264

MDL-100240	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.

HY-106844A

(+)-EMD 57033	Others	Cardiovascular Disease
(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca ²⁺ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .

Cat. No.	Product Name	Type

HY-W145695

Chitoheptaose	Biochemical Assay Reagents
Chitoheptaose is a chitosan oligosaccharide. Chitoheptaose is capable of extracting exoskeletons from crustaceans, such as the shells of crabs, shrimp and lobsters. Chitoheptaose has antioxidant, anti-inflammatory and anti-apoptotic activities and can be used in the study of myocarditis. Chitoheptaose has cardioprotective effects and improves cardiac parameters (left ventricular internal size, end-systolic and end-diastolic, ejection fraction and shortening fraction), inflammatory cytokines (IL-1β) in vanishing models .

Chitoheptaose

Biochemical Assay Reagents

Chitoheptaose is a chitosan oligosaccharide. Chitoheptaose is capable of extracting exoskeletons from crustaceans, such as the shells of crabs, shrimp and lobsters. Chitoheptaose has antioxidant, anti-inflammatory and anti-apoptotic activities and can be used in the study of myocarditis. Chitoheptaose has cardioprotective effects and improves cardiac parameters (left ventricular internal size, end-systolic and end-diastolic, ejection fraction and shortening fraction), inflammatory cytokines (IL-1β) in vanishing models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-101415

Coenzyme Q9 Ubiquinone Q9; CoQ9; Ubiquinone 9	Cardiovascular Disease Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Endogenous metabolite Disease Research Fields	Apoptosis Endogenous Metabolite
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

HY-101415R

Coenzyme Q9 (Standard)	Quinones Structural Classification Microorganisms Source classification Benzene Quinones Endogenous metabolite	Apoptosis Endogenous Metabolite
Coenzyme Q9 (Standard) is the analytical standard of Coenzyme Q9. This product is intended for research and analytical applications. Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

Cat. No.	Product Name	Chemical Structure

HY-B0259S3

Indapamide-d6
Indapamide-d6 is a deuterated labeled Indapamide . Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-B0259S

(rac)-Indapamide-d3
(rac)-Indapamide-d₃ is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy[1][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

left ventricular

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products